Company Overview and News
Wells Fargo plans to trim its workforce by about 5 to 10 percent within three years as CEO Tim Sloan works to pull the San Francisco bank clear of customer-abuse scandals and prop up a lagging stock price.
As the major indexes flirt with new all-time highs, investors understandably have been wondering how far this bull market has to run. While prognostications abound about what “inning” we are in – to use the popular baseball analogy – the answer is that no one really knows, even though all signs point toward continued economic expansion and the rising share values that accompany it.
WFC WFCNP BRK.A BK
American memory and storage tech firm Micron (MU - Free Report) has released fiscal Q4 2018 (ended August) earnings after Thursday's closing bell, with typically positive results: earnings of $3.53 per share easily beat the Zacks consensus of $3.32, with year-over-year earnings growth up 75%. Quarterly sales posted $8.44 billion, which is not only well above the estimated $8.25 billion but even higher than the top on the previously guided revenue range of $8.
United Natural Foods (UNFI - Free Report) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items.
WFC WFCNP CMD UNFI CMN
Ryan’s commentary in this video series is typically focused on growth and income, and this week’s featured stocks—Lockheed Martin (LMT - Free Report) and Innovative Industrial Properties (IIPR - Free Report) —are certainly two dividend-paying stocks with great earnings expansion prospects.
WFC WFCNP LMT IIPR
Exelixis, Inc. (EXEL - Free Report) along with its partner Ipsen Biopharmaceuticals Canada announced that Health Canada has approved Cabometyx (cabozantinib) tablets for the treatment of advanced renal cell carcinoma (RCC) in adult patients, previously treated with vascular endothelial growth factor targeted therapy.
WFC WFCNP EXEL GILD RHT NVS CSIQ
Disney (DIS - Free Report) shares popped 1.7% following news that its ESPN+ streaming service reached over one million paying subscribers. This announcement from the struggling sports media giant led to a boost in DIS stock, but the new stand-alone ESPN streaming service's growth since its April launch is also a sign that Disney’s streaming future looks secure.
WFC WFCNP FB NFLX TWTR AAPL
Accenture plc (ACN - Free Report) yesterday announced the launch of Innovation Center for Salesforce (CRM - Free Report) . The center focuses on demonstrating new ways of applying Salesforce technologies to improve end-user experiences, capture data through transactions and deliver value for customers. Service bots and artificial intelligence (Salesforce Einstein AI) as well as virtual reality-based demonstrations will be used for visual storytelling and interactive demonstrations across industries.
WFC WFCNP FCN RHT ACN CSIQ CRAI
Equinor ASA (EQNR - Free Report) has awarded a drilling contract to a subsidiary of Seadrill Ltd. SDRL, Seadrill Norway Operations Ltd, for the use of semi-submersible rig, West Hercules. The contract relates to drilling of two exploration wells in the Barents Sea with options for drilling nine additional wells. Drilling is anticipated to commence in the spring of 2019. The rig is mainly allocated for exploration drilling.
HLX WFC WFCNP SDLP XOM RHT SDRL CSIQ
On Sep 19, we issued an updated research report on Abbott Laboratories (ABT - Free Report) . Notably, branded generics and international diabetes businesses of Abbott should drive growth in the coming quarters. Nevertheless, a competitive environment persists to raise concerns for Abbott. The stock carries a Zacks Rank #3 (Hold).
ABT WFC WFCNP ISRG ABT RHT VEEV ATHN CSIQ
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET